Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Informatics » Paradigm, Nanogen, Sangamo File for IPO, Many Others Get Ready

Paradigm, Nanogen, Sangamo File for IPO, Many Others Get Ready

Feb 24, 2000
Premium

W

ASHINGTON--The list of genomics companies planning initial public offerings continues to grow, with Paradigm Genetics, Nanogen, and Sangamo Biosciences about to join the fray. All three have filed IPO registration statements with the Securities and Exchange Commission.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Mix of Human and Monkey

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

Fetal Tissue Policy Changes Expected

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

Science Papers on Approach to Isolate DNA from Sediment, Algorithm to Construct Signaling Networks

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Sequencing the Zoo

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.

Apr
28
Featured Webinar

Spatial Multiomics: Analysis Strategies for Enriching Single-Cell Phenotyping Data: Integrative Analysis of Single-Cell Omics and Imaging Data

Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development. 

May
04
Featured Webinar

Spatial Multiomics: Analysis Strategies for Enriching Single-Cell Phenotyping Data: Transcriptome-Guided Analysis of Highly Multiplexed Immunohistochemistry Images

Sponsored by
Akoya Biosciences

Recently developed technologies for digital imaging and highly multiplexed immunohistochemistry (mIHC) advancing the field of histology into a quantitative era, allowing for more complex descriptions of tissue architecture.

May
06
Featured Webinar

Spatial Multiomics: Analysis Strategies for Enriching Single-Cell Phenotyping Data: Enriching Spatial Proteomic Data with Parallel CITE-seq Analysis Elucidates Multiomic Changes with Aging

Sponsored by
Akoya Biosciences

Integrating complementary data sets provides a powerful tool to study complex biological processes.

May
11
Featured Webinar

Spatial Multiomics: Analysis Strategies for Enriching Single-Cell Phenotyping Data: Panel Discussion: Analysis Strategies for Enriching Single-Cell Spatial Phenotyping Data

Sponsored by
Akoya Biosciences

Our expert panelists will review their own strategies for addressing the challenges of integrative multiomic analysis and will share best practices for this rapidly evolving field.

What's Popular?

In Informatics

  1. Biden Administration Commits $1.7B to SARS-CoV-2 Variant Sequencing, Surveillance

  2. French Single-Cell Analysis Startup Minos Biosciences Raises €1.5M

  3. Trapelo Health, Magellan Hope to Ease Prior Authorization for Precision Oncology Testing

    Premium

  4. Benchling Raises $200M in Series E Funding Round

  5. Rosalind Partners with Geninus, Helixrus to Bring Single-Cell Software to Asian Markets

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.